Edesa Biotech Cash Flow Statement

Financials in millions USD. Fiscal year is October - September.

Millions USD. Fiscal year is Oct - Sep.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Sep '25 Sep 30, 2025	Sep '24 Sep 30, 2024	Sep '23 Sep 30, 2023	Sep '22 Sep 30, 2022	Sep '21 Sep 30, 2021
Net Income	-7.82	-7.19	-6.17	-8.37	-17.55	-13.34
Depreciation & Amortization	0.1	0.12	0.19	0.18	0.12	0.12
Stock-Based Compensation	1.05	0.73	0.54	1.25	2.26	3.2
Other Operating Activities	-	-	-0.01	-	-	-
Change in Accounts Receivable	-0.06	-0.38	0.36	0.56	2.03	-3.23
Change in Accounts Payable	-1.07	-0.72	0.02	-0.56	0.88	-0.12
Change in Other Net Operating Assets	-0.09	0.11	0.2	0.3	-0.02	-0.28
Operating Cash Flow	-7.89	-7.32	-4.89	-6.64	-12.28	-13.66
Capital Expenditures	-	-	-	-	-0.01	-0.01
Investing Cash Flow	-	-	-	-	-0.01	-0.01
Long-Term Debt Repaid	-	-	-0.03	-	-	-
Net Debt Issued (Repaid)	-	-	-0.03	-	-	-
Issuance of Common Stock	10.59	7.72	0.73	5.12	11.96	14.36
Other Financing Activities	-0.61	-0.57	-0.11	-0.29	-0.33	-0.19
Financing Cash Flow	18.31	17.03	0.59	4.83	11.63	14.17
Foreign Exchange Rate Adjustments	0.07	0.05	-0.03	0.08	-0.09	0.12
Net Cash Flow	10.49	9.75	-4.32	-1.73	-0.75	0.63
Free Cash Flow	-7.89	-7.32	-4.89	-6.64	-12.28	-13.67
Free Cash Flow Per Share	-1.16	-1.29	-1.53	-2.32	-5.86	-7.92
Levered Free Cash Flow	-5.37	-4.91	-3.16	-3.78	-6.12	-14.93
Unlevered Free Cash Flow	-5.37	-4.91	-3.16	-3.78	-6.12	-14.93
Change in Working Capital	-1.23	-0.99	0.57	0.31	2.89	-3.64

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q